Behavior of hospitalized severe influenza cases according to the outcome variable in Catalonia, Spain, during the 2017–2018 season

• Published in: Scientific reports Vol. 11; no. 1; p. 13587
• Main Authors: Soldevila, Núria, Acosta, Lesly, Martínez, Ana, Godoy, Pere, Torner, Núria, Rius, Cristina, Jané, Mireia, Domínguez, Angela
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 30.06.2021; Nature Publishing Group; Nature Portfolio
• Subjects: 692/499; 692/699/255; 692/699/255/1578; Death; Epidemiology; Exo-a-sialidase; Hospitalization; Humanities and Social Sciences; Influenza; Laboratories; Mortality; multidisciplinary; Patients; Regression analysis; Science; Science (multidisciplinary); Seasons
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-021-92895-5

Influenza is an important cause of severe illness and death among patients with underlying medical conditions and in the elderly. The aim of this study was to investigate factors associated with ICU admission and death in patients hospitalized with severe laboratory-confirmed influenza during the 2017–2018 season in Catalonia. An observational epidemiological case-to-case study was carried out. Reported cases of severe laboratory-confirmed influenza requiring hospitalization in 2017–2018 influenza season were included. Mixed-effects regression analysis was used to estimate the factors associated with ICU admission and death. A total of 1306 cases of hospitalized severe influenza cases were included, of whom 175 (13.4%) died and 217 (16.6%) were ICU admitted. Age 65–74 years and ≥ 75 years and having ≥ 2 comorbidities were positively associated with death (aOR 3.19; 95%CI 1.19–8.50, aOR 6.95, 95%CI 2.76–1.80 and aOR 1.99; 95%CI 1.12–3.52, respectively). Neuraminidase inhibitor treatment and pneumonia were negatively associated with death. The 65–74 years and ≥ 75 years age groups were negatively associated with ICU admission (aOR 0.41; 95%CI 0.23–0.74 and aOR 0.30; 95%CI 0.17–0.53, respectively). A factor positively associated with ICU admission was neuraminidase inhibitor treatment. Our results support the need to investigate the worst outcomes of hospitalized severe cases, distinguishing between death and ICU admission.